105 related articles for article (PubMed ID: 24561703)
41. A calorimetric study of the binding of lisinopril, enalaprilat and captopril to angiotensin-converting enzyme.
Andújar-Sánchez M; Cámara-Artigas A; Jara-Pérez V
Biophys Chem; 2004 Oct; 111(2):183-9. PubMed ID: 15381315
[TBL] [Abstract][Full Text] [Related]
42. A clinical pharmacological study of nifedipine and lisinopril alone and in combination.
Lees KR; Meredith PA; Reid JL
J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S105-7. PubMed ID: 2455105
[TBL] [Abstract][Full Text] [Related]
43. Tryptophan-containing dipeptides are C-domain selective inhibitors of angiotensin converting enzyme.
Lunow D; Kaiser S; Rückriemen J; Pohl C; Henle T
Food Chem; 2015 Jan; 166():596-602. PubMed ID: 25053098
[TBL] [Abstract][Full Text] [Related]
44. Antihypertensive properties of a new long-acting angiotensin converting enzyme inhibitor in renin-dependent and independent hypertensive models.
Nagata S; Takeyama K; Fukuya F; Nagai R; Hosoki K; Nishimura K; Deguchi T; Karasawa T
Arzneimittelforschung; 1995 Aug; 45(8):853-8. PubMed ID: 7575746
[TBL] [Abstract][Full Text] [Related]
45. Development of domain-selective angiotensin I-converting enzyme inhibitors.
Redelinghuys P; Nchinda AT; Sturrock ED
Ann N Y Acad Sci; 2005 Nov; 1056():160-75. PubMed ID: 16387685
[TBL] [Abstract][Full Text] [Related]
46. Plasma Kallikrein and Angiotensin I-converting enzyme N- and C-terminal domain activities are modulated by the insertion/deletion polymorphism.
Almeida SS; Barros CC; Moraes MR; Russo FJ; Haro AS; Rosa TS; Alves MF; Pesquero JB; Carmona AK; Bacurau RF; Araújo RC
Neuropeptides; 2010 Apr; 44(2):139-43. PubMed ID: 20064660
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs.
King JN; Mauron C; Kaiser G
Am J Vet Res; 1995 Dec; 56(12):1620-8. PubMed ID: 8599524
[TBL] [Abstract][Full Text] [Related]
48. Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design.
Corradi HR; Schwager SL; Nchinda AT; Sturrock ED; Acharya KR
J Mol Biol; 2006 Mar; 357(3):964-74. PubMed ID: 16476442
[TBL] [Abstract][Full Text] [Related]
49. Nicotianamine is a novel angiotensin-converting enzyme 2 inhibitor in soybean.
Takahashi S; Yoshiya T; Yoshizawa-Kumagaye K; Sugiyama T
Biomed Res; 2015; 36(3):219-24. PubMed ID: 26106051
[TBL] [Abstract][Full Text] [Related]
50. Advances in Structural Biology of ACE and Development of Domain Selective ACE-inhibitors.
Polakovičová M; Jampílek J
Med Chem; 2019; 15(6):574-587. PubMed ID: 31084594
[TBL] [Abstract][Full Text] [Related]
51. Angiotensin-converting enzyme inhibitors, inhibition of brain and peripheral angiotensin-converting enzymes, and left ventricular dysfunction in rats after myocardial infarction.
Ahmad M; White R; Tan J; Huang BS; Leenen FH
J Cardiovasc Pharmacol; 2008 Jun; 51(6):565-72. PubMed ID: 18496146
[TBL] [Abstract][Full Text] [Related]
52. Angiotensin converting enzyme immobilized on magnetic beads as a tool for ligand fishing.
de Almeida FG; Vanzolini KL; Cass QB
J Pharm Biomed Anal; 2017 Jan; 132():159-164. PubMed ID: 27728854
[TBL] [Abstract][Full Text] [Related]
53. Design, synthesis and evaluation of novel 2-butyl-4-chloroimidazole derived peptidomimetics as Angiotensin Converting Enzyme (ACE) inhibitors.
Jallapally A; Addla D; Bagul P; Sridhar B; Banerjee SK; Kantevari S
Bioorg Med Chem; 2015 Jul; 23(13):3526-33. PubMed ID: 25922179
[TBL] [Abstract][Full Text] [Related]
54. Structural basis of the lisinopril-binding specificity in N- and C-domains of human somatic ACE.
Fernandez JH; Hayashi MA; Camargo AC; Neshich G
Biochem Biophys Res Commun; 2003 Aug; 308(2):219-26. PubMed ID: 12901857
[TBL] [Abstract][Full Text] [Related]
55. Molecular dynamics simulation and molecular docking studies of Angiotensin converting enzyme with inhibitor lisinopril and amyloid Beta Peptide.
Jalkute CB; Barage SH; Dhanavade MJ; Sonawane KD
Protein J; 2013 Jun; 32(5):356-64. PubMed ID: 23660814
[TBL] [Abstract][Full Text] [Related]
56. Structure-function studies of BPP-BrachyNH
Arcanjo DDR; Vasconcelos AG; Nascimento LA; Mafud AC; Plácido A; Alves MMM; Delerue-Matos C; Bemquerer MP; Vale N; Gomes P; Oliveira EB; Lima FCA; Mascarenhas YP; Carvalho FAA; Simonsen U; Ramos RM; Leite JRSA
Eur J Med Chem; 2017 Oct; 139():401-411. PubMed ID: 28810191
[TBL] [Abstract][Full Text] [Related]
57. Fluorescence polarization studies of different forms of angiotensin-converting enzyme.
Voronov SV; Binevski PV; Eremin SA; Kost OA
Biochemistry (Mosc); 2001 Jul; 66(7):788-94. PubMed ID: 11563960
[TBL] [Abstract][Full Text] [Related]
58. The Dynamic Nonprime Binding of Sampatrilat to the C-Domain of Angiotensin-Converting Enzyme.
Sharma RK; Espinoza-Moraga M; Poblete H; Douglas RG; Sturrock ED; Caballero J; Chibale K
J Chem Inf Model; 2016 Dec; 56(12):2486-2494. PubMed ID: 27959521
[TBL] [Abstract][Full Text] [Related]
59. N- versus C-domain selectivity of catalytic inactivation of human angiotensin converting enzyme by lisinopril-coupled transition metal chelates.
Hocharoen L; Joyner JC; Cowan JA
J Med Chem; 2013 Dec; 56(24):9826-36. PubMed ID: 24228790
[TBL] [Abstract][Full Text] [Related]
60. Probing the basis of domain-dependent inhibition using novel ketone inhibitors of Angiotensin-converting enzyme.
Watermeyer JM; Kröger WL; O'Neill HG; Sewell BT; Sturrock ED
Biochemistry; 2008 Jun; 47(22):5942-50. PubMed ID: 18457420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
